Shu, Mengjun
Yan, Hongbin
Xu, Chuanying
Wu, Yan
Chi, Zhaohua
Nian, Weihong
He, Zhuzi
Xiao, Jing
Wei, Hongli
Zhou, Qing
Zhou, Joe X.
Article History
Received: 9 April 2019
Accepted: 4 February 2020
First Online: 19 February 2020
Competing interests
: All authors are current or former employees of Genor Biopharma Co., Ltd., which has the ownership of GB235 drug candidate. The authors declare no competing interests.